For research use only. Not for use in humans.

Frovocimab (Anti-PCSK9)

Synonyms: LY 3015014 Cat.No.A2876

Frovocimab (Anti-PCSK9) is a humanized IgG4 monoclonal antibody that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). MW: 146.88 KD.

Frovocimab (Anti-PCSK9)

Quality Control

Specificity

Name	Citation	PCSK9
PF-06446846	0	+++
PF-06446846 hydrochloride	0	✔
SBC-110736	0	✔
R-IMPP	0	✔
SBC-115076	9	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Frovocimab (Anti-PCSK9) is a humanized IgG4 monoclonal antibody that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). MW: 146.88 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26392590/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1643672-70-1
Molecular Weight	146.88
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.